Report top line data for the alvelestat Phase 2 proof-of-concept study
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 10 Feb 2021
- Due
- 31 Dec 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“for which the Company expects to report top line data in the second half of 2021”
What we found
Evidence strength A What the grades mean
The company delayed the reporting of top-line data for the Phase 2 alvelestat study from the second half of 2021 to May 2022 due to enrollment impacts from the COVID-19 pandemic.
-
A Mereo Biopharma Group plc 20-F filed 2022-03-31
“our Phase 2 alvelestat trial has been delayed with top-line data now expected in early Q2 2022.” ✓ confirmed on the page
-
A Mereo Biopharma Group plc 20-F filed 2023-03-28
“We reported successful top-line data from a Phase 2 proof-of-concept clinical trial of alvelestat for the treatment of severe AATD-LD in May 2022” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- alvelestat Phase 2 top line data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Mereo Biopharma Group plc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MREO-023445 · Corrections policy